Heat Biologics Inc. buy melinda
Startpreis
24.11.18
/
50%
8,97 €
Kursziel
22.01.19
12,63 €
Rendite (%)
-4,23 %
Endpreis
22.01.19
8,59 €
Zusammenfassung
Diese Einschätzung wurde am 22.01.19 mit einem Endkurs von 8,59 € beendet. Leicht abwärts ging es für die BUY Einschätzung von melinda zu Heat Biologics Inc. mit einer Rendite von -4,23 %. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Heat Biologics Inc. | 5,96 % | 5,96 % | -75,94 % | -97,27 % |
iShares Core DAX® | 2,59 % | -1,16 % | 14,78 % | 16,81 % |
iShares Nasdaq 100 | 3,55 % | -1,73 % | 43,26 % | 44,23 % |
iShares Nikkei 225® | 0,69 % | -8,35 % | 18,45 % | 1,36 % |
iShares S&P 500 | 2,21 % | -0,94 % | 31,36 % | 42,81 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Heat Biologics Inc. diskutieren
SecteurRecherche biotechnologique et médicale
Operates as a clinical stage biopharmaceutical company with interest in the development of novel allogeneic drugs
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer.
The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness.
Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.
The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer.
The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness.
Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.
The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.
Nombre d'employés : 19 personnes.
(Vom Mitglied beendet)
Beendete Einschätzungen von melinda zu Heat Biologics Inc.
Heat Biologics Inc.
Startkurs
Kursziel
Rendite (%)
66,20 €
13.03.17
13.03.17
75,77 €
13.09.17
13.09.17
-44,67 %
13.09.17
13.09.17